Dissecting Bortezomib: Development, Application, Adverse Effects and Future Direction

被引：28
作者：
Cao, Biyin [1 ]
Li, Jie [1 ]
Mao, Xinliang [1 ]
机构：
[1] Soochow Univ, Cyrus Tang Hematol Ctr, Jiangsu Inst Hematol, Affiliated Hosp 1, Suzhou 215123, Jiangsu, Peoples R China
来源：
CURRENT PHARMACEUTICAL DESIGN | 2013年 / 19卷 / 18期
关键词：
Proteasome inhibitor; bortezomib; adverse effect; resistance; NF-KAPPA-B; PROTEASOME INHIBITOR BORTEZOMIB; ENDOPLASMIC-RETICULUM STRESS; UNFOLDED PROTEIN RESPONSE; PHASE-I TRIAL; MULTIPLE-MYELOMA; CHEMOTHERAPEUTIC-AGENTS; PERIPHERAL NEUROPATHY; SUBSTRATE-SPECIFICITY; MULTIDRUG-RESISTANCE;
D O I：
10.2174/13816128113199990338
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Bortezomib is the first-in-class proteasome inhibitor which has been used worldwide for the treatment of multiple myeloma and mantle cell lymphoma. Bortezomib is under evaluation as a single agent or in combination with other drugs for solid cancers and stem cell transplantation in clinical settings. However, adverse effects and drug resistance have been observed in patients, which is now emerging as a great challenge for the extended application of bortezomib. In this review, we will comprehensively discuss the development of bortezomib, the mechanism underlying its therapeutics, adverse effects and resistance. Second generation of bortezomib and its future directions will also be discussed.
引用
收藏
页码：3190 / 3200
页数：11
相关论文
共 124 条
[1]   Development of the proteasome inhihitor Veleade™ (Bortezomib) [J].
Adams, J ;
Kauffman, M .
CANCER INVESTIGATION, 2004, 22 (02) :304-311
[2]   Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acids [J].
Adams, J ;
Behnke, M ;
Chen, SW ;
Cruickshank, AA ;
Dick, LR ;
Grenier, L ;
Klunder, JM ;
Ma, YT ;
Plamondon, L ;
Stein, RL .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (04) :333-338
[3]   Early Tumor Progression Associated with Enhanced EGFR Signaling with Bortezomib, Cetuximab, and Radiotherapy for Head and Neck Cancer [J].
Argiris, Athanassios ;
Duffy, Austin G. ;
Kummar, Shivaani ;
Simone, Nicole L. ;
Arai, Yoshio ;
Kim, Seungwon W. ;
Rudy, Susan F. ;
Kannabiran, Vishnu R. ;
Yang, Xinping ;
Jang, Minyoung ;
Chen, Zhong ;
Suksta, Nanette ;
Cooley-Zgela, Theresa ;
Ramanand, Susmita G. ;
Ahsan, Aarif ;
Nyati, Mukesh K. ;
Wright, John J. ;
Van Waes, Carter .
CLINICAL CANCER RESEARCH, 2011, 17 (17) :5755-5764
[4]   Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature [J].
Argyriou, Andreas A. ;
Iconomou, Gregoris ;
Kalofonos, Haralabos P. .
BLOOD, 2008, 112 (05) :1593-1599
[5]   Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma [J].
Arnulf, Bertrand ;
Pylypenko, Halyna ;
Groslcki, Sebastian ;
Karamanesht, Ievgenii ;
Leleu, Xavier ;
van de Velde, Helgi ;
Feng, Huaibao ;
Cakana, Andrew ;
Deraedt, William ;
Moreau, Philippe .
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (12) :1925-1928
[6]   DangER: protein ovERload. Targeting protein degradation to treat myeloma [J].
Aronson, Lauren I. ;
Davies, Faith E. .
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (08) :1119-1130
[7]   Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma [J].
Badros, Ashraf ;
Burger, Angelika M. ;
Philip, Sunita ;
Niesvizky, Ruben ;
Kolla, Sarah S. ;
Goloubeva, Olga ;
Harris, Carolynn ;
Zwiebel, James ;
Wright, John J. ;
Espinoza-Delgado, Igor ;
Baer, Maria R. ;
Holleran, Julianne L. ;
Egorin, Merrill J. ;
Grant, Steven .
CLINICAL CANCER RESEARCH, 2009, 15 (16) :5250-5257
[8]  
Baiocchi RA, 2010, PHASE 2 TRIAL RITUXI
[9]   Proteasomal AAA-ATPases: Structure and function [J].
Bar-Nun, Shoshana ;
Glickman, Michael H. .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2012, 1823 (01) :67-82
[10]   A fourth IκB protein within the NF-κB signaling module [J].
Basak, Soumen ;
Kim, Hana ;
Kearns, Jeffrey D. ;
Tergaonkar, Vinay ;
O'Dea, Ellen ;
Werner, Shannon L. ;
Benedict, Chris A. ;
Ware, Carl F. ;
Ghosh, Gourisankar ;
Verma, Inder M. ;
Hoffmann, Alexander .
CELL, 2007, 128 (02) :369-381
12345678910